NCT05177432: QUEST

Quadratic Phenotypic Optimisation Platform (QPOP) Utilisation to Enhance Selection of Patient Therapy Through Patient Derived Organoids in Breast Cancer

Status unknown Phase 1 Last updated 18 April 2023

What this trial tests

Phase 1 trial testing QPOP in Breast Cancer in 26 participants. Status unknown.

Timeline

6 December 2021

Primary endpoint
3 January 2025

31 December 2025

Quick facts

Lead sponsor	National University Hospital, Singapore
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	6 December 2021
Primary completion	3 January 2025
Estimated completion	31 December 2025
Sites	1 location across Singapore

Drugs / interventions tested

• QPOP

Conditions studied

• Breast Cancer — all drugs for Breast Cancer →

Sponsor

National University Hospital, Singapore

Who can join

Adults 21 to 99, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Based on proof-of-concept study, the investigators hypothesise that the QPOP prediction model can be further extended into use in solid tumors. Using breast cancer as a model, the investigators intend to investigate the feasibility of QPOP as a clinical decision support platform to identify patient-specific drug combinations across a range of breast cancer patients. The investigators propose a pilot phase I clinical study to test the feasibility of using QPOP to guide therapy in patients with advanced breast cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Human disease models in drug development.
   Loewa A, Feng JJ, Hedtrich S. · · 2023 · cited 164× · PMID 37359774 · DOI 10.1038/s44222-023-00063-3
2. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.
   Thorel L, Perréard M, Florent R, Divoux J, et al · · 2024 · cited 90× · PMID 38945959 · DOI 10.1038/s12276-024-01272-5
3. Clinical translation of patient-derived tumour organoids- bottlenecks and strategies.
   Foo MA, You M, Chan SL, Sethi G, et al · · 2022 · cited 61× · PMID 35272694 · DOI 10.1186/s40364-022-00356-6
4. Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine.
   Derouane F, van Marcke C, Berlière M, Gerday A, et al · · 2022 · cited 54× · PMID 36010869 · DOI 10.3390/cancers14163876
5. Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
   Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735
6. Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
   Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656
7. A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine.
   Kalla J, Pfneissl J, Mair T, Tran L, et al · · 2025 · cited 13× · PMID 38806997 · DOI 10.1007/s13402-024-00960-8
8. Opportunities and challenges for patient-derived models of brain tumors in functional precision medicine.
   Mann B, Artz N, Darawsheh R, Kram DE, et al · · 2025 · cited 12× · PMID 39953052 · DOI 10.1038/s41698-025-00832-w